Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factory Receivetor 2B Positive First-Line Gastric

Published: 2025-06-30 15:20:33 ET AMGN

Published on 06/30/2025 at 15:20

Amgen announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive.